These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 31882243)

  • 1. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
    Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
    Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
    Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer landscape of
    Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site.
    Junior JNA; Preto DD'; Lazarini MEZN; de Lima MA; Bonatelli M; Berardinelli GN; da Silva VD; Pinheiro C; Reis RM; Cárcano FM
    Int J Clin Oncol; 2024 Jun; 29(6):726-734. PubMed ID: 38528294
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Li L; Yue P; Zhu J; Li L; Wang K; Yuan G; Song Y
    Cancer Invest; 2024 Apr; 42(4):297-308. PubMed ID: 38666471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
    Rudd ML; Hansen NF; Zhang X; Urick ME; Zhang S; Merino MJ; ; Mullikin JC; Brody LC; Bell DW
    PLoS One; 2022; 17(1):e0251286. PubMed ID: 35081118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
    Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden.
    Choi J; Park KH; Kim YH; Sa JK; Sung HJ; Chen YW; Chen Z; Li C; Wen W; Zhang Q; Shu XO; Zheng W; Kim JS; Guo X
    Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):712-720. PubMed ID: 38393316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types.
    Miyashita H; Bevins NJ; Thangathurai K; Lee S; Pabla S; Nesline MK; Glenn ST; Conroy JM; DePietro P; Rubin E; Sicklick JK; Kato S; Kurzrock R
    Am J Cancer Res; 2024; 14(5):2240-2252. PubMed ID: 38859855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherapy outcomes.
    Ying L; Hu Z; Lu Y; Tao Q; Xiong F; Shu Y; Yang Y; Qiao X; Peng C; Jiang Y; Han M; Xu M; Li X; Wang D
    Oncoimmunology; 2024; 13(1):2303195. PubMed ID: 38235318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low- and high-stage tumours.
    McHenry A; Devereaux K; Ryan E; Chow S; Allard G; Ho CC; Suarez CJ; Folkins A; Yang E; Longacre TA; Charu V; Howitt BE
    Histopathology; 2024 Jun; ():. PubMed ID: 38859768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
    Mittica G; Ghisoni E; Giannone G; Aglietta M; Genta S; Valabrega G
    Oncotarget; 2017 Oct; 8(52):90532-90544. PubMed ID: 29163851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy.
    Miyashita H; Kurzrock R; Bevins NJ; Thangathurai K; Lee S; Pabla S; Nesline M; Glenn ST; Conroy JM; DePietro P; Rubin E; Sicklick JK; Kato S
    NPJ Genom Med; 2023 Aug; 8(1):19. PubMed ID: 37553332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
    Bergom HE; Sena LA; Day A; Miller B; Miller CD; Lozada JR; Zorko N; Wang J; Shenderov E; Lobo FP; Caramella-Pereira F; Marchionni L; Drake CG; Lotan T; De Marzo AM; Hwang J; Antonarakis ES
    NPJ Genom Med; 2024 Jan; 9(1):7. PubMed ID: 38253539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer.
    Kamatham S; Shahjehan F; Kasi PM
    Front Pharmacol; 2020; 11():23. PubMed ID: 32116700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
    Makker V; Taylor MH; Aghajanian C; Oaknin A; Mier J; Cohn AL; Romeo M; Bratos R; Brose MS; DiSimone C; Messing M; Stepan DE; Dutcus CE; Wu J; Schmidt EV; Orlowski R; Sachdev P; Shumaker R; Casado Herraez A
    J Clin Oncol; 2020 Sep; 38(26):2981-2992. PubMed ID: 32167863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
    Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
    Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
    Shao C; Li G; Huang L; Pruitt S; Castellanos E; Frampton G; Carson KR; Snow T; Singal G; Fabrizio D; Alexander BM; Jin F; Zhou W
    JAMA Netw Open; 2020 Oct; 3(10):e2025109. PubMed ID: 33119110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.